Merz Announces the Commercial Launch of the Cellfina® System in Europe
Merz today announced the commercial availability of the Cellfina® System in select European markets. The Cellfina® System is currently the only EU CE-Marked and U.S. FDA-cleared minimally-invasive procedure that treats the underlying structural cause of cellulite with results that last at least three years. Cellfina® is intended for long-term reduction of cellulite by precise release of targeted structural tissue (fibrous septae).
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170914005588/en/
Recent market research conducted by Merz confirms that cellulite is a widespread concern for women globally1. A majority of women (ages 25-60) surveyed in the United Kingdom, Germany, France, Spain, Russia and Italy reported “somewhat to extreme concern” about the condition.
“Cellulite treatment is an aesthetic category where the market need has remained largely unmet and where patients have often been dissatisfied with available options,” said Stefan Brinkmann, Vice President and Regional Head for Merz in EMEA. “With the introduction of the Cellfina® System to the European market, Merz is now able to provide physicians with a technology that delivers an effective and long-term solution to the problem of cellulite dimples.”
A truly revolutionary aesthetic treatment, Cellfina® requires a single in-office procedure and combines highly advanced, proprietary technology with a well-established procedure called subcision to treat the underlying structural problem that causes cellulite.
“At Merz, we are well aware that science-backed treatment options that treat the underlying cause of cellulite are of paramount importance to patients and physicians alike,” said Yannick Grosskreutz, Vice President and Head of Global Marketing. “Clinical trial data shows that Cellfina® delivers consistently high aesthetic improvement and patient satisfaction rates even three years after the initial treatment session, evidence that the Cellfina® System meets the high standard of quality and efficacy that our customers have come to expect from the Merz portfolio.”
In the US IDE pivotal study, 55 patients underwent a single treatment. The Cellfina® System improved the appearance of cellulite in 97% of treated patients at three years, according to independent physician evaluators. Importantly, 93% of patients reported satisfaction with their treatment at the three year mark, and noticeable improvement on the Global Aesthetic Improvement Scale (GAIS) was seen in 100% of treated patients at three years. The most common side effects reported were soreness, tenderness and bruising; these side effects resolved quickly with time.
About Cellfina ®
The Cellfina® System is intended for long-term reduction of cellulite, up to three years, by precise release of targeted structural tissue (fibrous septae). Safety and effectiveness in other anatomical areas have not been established. The most common side effects reported were soreness, tenderness and bruising. The Cellfina® System is only available through a licensed physician. For full product and safety information, refer to the Instructions for Use.
With approximately 3,000 employees and 34 subsidiaries worldwide, Merz is a Global leader in Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. Complementing its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy for the treatment of movement disorders. Skincare products and a range of OTC medicines are also included in offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2015/16, Merz Pharma Group generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.
1 Data on file
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Guy Carpenter Names Ross Howard Vice Chairman20.11.2018 20:46 | Tiedote
Guy Carpenter & Company, LLC, a leading global risk and reinsurance specialist and a wholly owned subsidiary of Marsh & McLennan Companies (NYSE: MMC), today announced a new leadership appointment from the Jardine Lloyd Thompson Group plc (JLT) reinsurance organization. Effective upon closing of the transaction between Guy Carpenter’s parent company, Marsh & McLennan Companies and JLT, which remains subject to the receipt of certain antitrust and financial regulatory approvals, Ross Howard, Chairman of JLT Re, will become Vice Chairman of Guy Carpenter, reporting to President & CEO Peter Hearn. Mr. Howard will also become a member of Guy Carpenter’s Executive Committee and will be responsible for developing new business opportunities and assisting with client relationships in order to continue the growth of the combined global reinsurance business. Additionally, Mr. Howard will also play a key role in executing the integration of JLT Re with Guy Carpenter. “We are very excited to take
IDEMIA Will Present Its 2018 Quarterly Financial Results to Investors on November 21, 201820.11.2018 20:31 | Tiedote
IDEMIA, the world leader in Augmented Identity, today announced that it will present its Q3 2018 financial results to investors on Wednesday November 21, 2018. Yann Delabrière (CEO), Frédéric Beylier (COO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 1:00 pm CET (12:00 pm London Time / 7:00 am New York Time). For more information, please refer to our website: http://investors.oberthur.com About IDEMIA OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable t
OCP Announces Date of Third Quarter 2018 Earnings20.11.2018 20:00 | Tiedote
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter 2018 results on Thursday, November 29, 2018. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 8:30 a.m. EST, 2:30 p.m. Morocco time (GMT+1), and 1:30 p.m. London time (GMT). OCP senior management will host a conference call to discuss third quarter 2018 results at 9:30 a.m. EST, 3:30 p.m. Morocco time (GMT+1), and 2:30 p.m. London time (GMT) on Thursday, November 29, 2018 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing email@example.com About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. O
Arch Insurance Announces Strategic Leadership Changes20.11.2018 18:50 | Tiedote
Arch Insurance (“Arch”) today announced Hugh Sturgess will assume the role of Chief Executive Officer, Arch Insurance International, effective Jan. 1, 2019, subject to regulatory approvals. Arch Insurance International includes Arch’s insurance operations in Europe, Bermuda and Australia. Mr. Sturgess has been with Arch Insurance since 2005 and is currently President and CEO of Arch Insurance Canada Ltd., where he has strategic and operational responsibility for a multi-line underwriting portfolio. Before joining Arch, Mr. Sturgess held various roles in the financial services industry, including tenures with the Royal Bank of Canada and Chubb Insurance Company of Canada. “Arch Insurance International underwrites a diverse portfolio of specialty insurance solutions across a number of geographies, with a key focus on providing value to our distribution partners and customers,” Mr. Sturgess said. “I look forward to the opportunity to work with our team in continuing to expand the value pr
Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc20.11.2018 17:33 | Tiedote
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received clearance from the European Commission (the “EC”) for the proposed acquisition of Shire plc (“Shire”) announced on May 8, 2018 (the “Acquisition”). The EC’s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance. Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda’s marketed product Entyvio (vedolizumab) and Shire’s pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights. The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition. SHP647 is an exciting pipeline compound
ResMed Elects Harjit Gill to Its Board of Directors20.11.2018 17:05 | Tiedote
ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service business solutions, today announced it has elected experienced consumer and healthcare executive Harjit Gill to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005179/en/ Harjit Gill, BA (Photo: Business Wire) Ms. Gill was elected by shareholders at its annual shareholder meeting last week in Sydney, Australia. Also, announced at that meeting, Gary W. Pace has retired from ResMed’s board after serving on it since July 1994. Ms. Gill’s appointment and Dr. Pace’s retirement both took effect Thursday, November 15. Ms. Gill has more than 25 years’ experience in health and consumer technology products as an executive, investor and regional business leader spanning Asia, Europe and the Middle East. From 1990 to 2015, she worked for Royal Philips as executive vice president and CEO for Phi
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme